Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
तुलना करने के लिए मीट्रिक्स | ALZN | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधALZNपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −1.0x | −1.9x | −0.6x | |
PEG अनुपात | −0.02 | 0.00 | 0.00 | |
क़ीमत/बुक | −6.1x | 1.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 7.3x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 348.0% | 48.9% | |
उचित मूल्य अपसाइड | अनलॉक करें | 24.4% | 7.2% | अनलॉक करें |